FDA Recommended Pre-BLA Meeting for Ersodetug
The FDA advised Rezolute to schedule a formal regulatory meeting following a review of additional clinical data.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Do you trust positive regulatory updates from biotech firms as a signal for long-term stock value?
The FDA has recommended that Rezolute request a Type B pre-BLA meeting to discuss its drug candidate Ersodetug. This regulatory milestone follows the submission of additional glucose-monitoring analysis for the treatment.
Why it matters
The FDA provided this recommendation after reviewing supplemental data that may indicate a clinical benefit, despite the drug failing to meet primary endpoints in the sunRIZE Phase 3 study. This meeting serves as a critical precursor to filing a formal Biologics License Application.
Rezolute shares saw an intraday jump of 10% following the announcement, contributing to an 84% surge in stock price year-to-date in 2026. The company has shifted resources from its RZ402 program to prioritize the development of Ersodetug.
The players
Rezolute
Rezolute is a biopharmaceutical company focused on the development of innovative therapies for metabolic diseases.
FDA
The Food and Drug Administration is the United States federal agency responsible for regulating biological products and medical devices.
The details
Rezolute is moving forward with Ersodetug while the sunRIZE open-label extension study remains ongoing. The company previously pivoted away from its RZ402 program for diabetic macular edema to consolidate resources toward the Ersodetug pipeline.
Timeline
October 5, 2026: Rezolute received the FDA pre-BLA meeting recommendation.
2026: The company stock price has surged more than 84% year-to-date.
Q4 2026: Topline results for the upLIFT Phase 3 trial are expected.
The Big Picture
This regulatory update aligns with the established FDA PDUFA-aligned Biologics License Application review process. The recommendation signals a formal shift toward the standard pathways required for drug approval in the United States.
The potential advancement of Ersodetug could eventually provide new therapeutic options for patients managing metabolic conditions. Until the BLA process concludes, patients should continue their current treatment regimens and consult with their providers regarding available clinical options.
The takeaway
The FDA recommendation provides a pathway for the company to seek approval despite previous clinical trial setbacks. Investors and patients should monitor the upcoming upLIFT trial results to determine the viability of the drug's path to market.
What happens next
Topline results for the upLIFT Phase 3 trial are scheduled for release during the fourth quarter of 2026.
Further reading
For more information on current treatment development, visit the Diabetes section.
Live Poll
Do you trust positive regulatory updates from biotech firms as a signal for long-term stock value?
